Patents by Inventor Ananth V. Annapragada
Ananth V. Annapragada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230398238Abstract: A liposomal composition (“ADx-003”) is provided, ADx-003 comprising a first phospholipid; a sterically bulky excipient that is capable of stabilizing the liposomal composition; a second phospholipid that is derivatized with a first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid that is derivatized with a second polymer, the second polymer being conjugated to a targeting ligand, the targeting ligand being represented by Formula I: wherein X is —CH2—, —CH2—CH2—, —CHO—, or —O—CO—; Y is —CH—CH?CH— or A and B are independently selected from C and N; R1, R2, R3, and R4 are independently selected from —H, halogen, —OH, and —CH3; and R5, R6, and R7 are independently selected from —H, halogen, —OH, —OCH3, —NO2, —N(CH3)2, C1-C6 alkyl, or a substituted or unsubstituted C4-C6 aryl group, except that when A and/or B is N the adjacent R5 and/or R7 is —H, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: August 24, 2023Publication date: December 14, 2023Applicants: Texas Children's Hospital, Alzeca Biosciences, LLCInventors: Eric A. Tanifum, Xianwei Sun, Ananth V. Annapragada, Carlo Medici
-
Patent number: 11779664Abstract: A liposomal composition (“ADx-003”) is provided, ADx-003 comprising a first phospholipid; a sterically bulky excipient that is capable of stabilizing the liposomal composition; a second phospholipid that is derivatized with a first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid that is derivatized with a second polymer, the second polymer being conjugated to a targeting ligand, the targeting ligand being represented by Formula I: wherein X is —CH2—, —CH2—CH2—, —CHO—, or —O—CO—; Y is —CH—CH?CH— or A and B are independently selected from C and N; R1, R2, R3, and R4 are independently selected from —H, halogen, —OH, and —CH3; and R5, R6, and R7 are independently selected from —H, halogen, —OH, —OCH3, —NO2, —N(CH3)2, C1-C6 alkyl, or a substituted or unsubstituted C4-C6 aryl group, except that when A and/or B is N the adjacent R5 and/or R7 is —H, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 5, 2022Date of Patent: October 10, 2023Assignees: Texas Children's Hospital, Alzeca Biosciences, LLCInventors: Eric A. Tanifum, Xianwei Sun, Ananth V. Annapragada, Carlo Medici
-
Publication number: 20230136718Abstract: Phospholipid-polymer-aromatic conjugates comprising binding ligands, liposome compositions including the phospholipid-polymer-aromatic conjugates, and binding ligands having an affinity for misfolded proteins are described. The phospholipid-polymer-aromatic conjugate may be represented by Structural Formula I: PL-AL-HP-X-BL (I). In Formula I, PL is a phospholipid, AL is an aliphatic linkage, HP is hydrophilic polymer, X is a link between the phospholipid-polymer and the binding ligand, and BL is polycyclic aromatic compound that functions as a binding ligand. The liposomal compositions may be useful for the imaging of misfolded and/or aggregated proteins.Type: ApplicationFiled: November 14, 2022Publication date: May 4, 2023Applicant: Alzeca Biosciences, LLCInventors: Ananth V. Annapragada, Peter Nilsson, Carlo Medici, Eric A. Tanifum
-
Publication number: 20220265868Abstract: A liposomal composition (“ADx-003”) is provided, ADx-003 comprising a first phospholipid; a sterically bulky excipient that is capable of stabilizing the liposomal composition; a second phospholipid that is derivatized with a first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid that is derivatized with a second polymer, the second polymer being conjugated to a targeting ligand, the targeting ligand being represented by Formula I: wherein X is —CH2—, —CH2—CH2—, —CHO—, or —O—CO—; Y is —CH—CH?CH— or A and B are independently selected from C and N; R1, R2, R3, and R4 are independently selected from —H, halogen, —OH, and —CH3; and R5, R6, and R7 are independently selected from —H, halogen, —OH, —OCH3, —NO2, —N(CH3)2, C1-C6 alkyl, or a substituted or unsubstituted C4-C6 aryl group, except that when A and/or B is N the adjacent R5 and/or R7 is —H, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 5, 2022Publication date: August 25, 2022Applicants: Texas Children's Hospital, Alzeca Biosciences, LLCInventors: Eric A. Tanifum, Xianwei Sun, Ananth V. Annapragada, Carlo Medici
-
Publication number: 20220023445Abstract: A liposomal composition (“ADx-001”) is provided, ADx-001 comprising a first phospholipid; a sterically bulky excipient that is capable of stabilizing the liposomal composition; a second phospholipid that is derivatized with a first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid that is derivatized with a second polymer, the second polymer being conjugated to a targeting ligand. The macrocyclic gadolinium-based imaging agent may be conjugated to a fourth phospholipid.Type: ApplicationFiled: August 16, 2021Publication date: January 27, 2022Applicant: Texas Children's HospitalInventors: Eric A. Tanifum, Ketankumar B. Ghaghada, Ananth V. Annapragada
-
Patent number: 11141495Abstract: Provided are aromatic compounds, phospholipid-polymer-aromatic conjugates comprising the aromatic compounds, and liposome compositions including the phospholipid-polymer-aromatic conjugates. The liposomal compositions may be useful for imaging of Alzheimer's Disease, for example, imaging of the amyloid-? plaque deposits characteristic of Alzheimer's Disease.Type: GrantFiled: February 14, 2020Date of Patent: October 12, 2021Assignee: Texas Children's HospitalInventors: Ananth V. Annapragada, Eric A. Tanifum, Mayank Srivastava
-
Patent number: 11116854Abstract: A liposomal composition (“ADx-001”) is provided, ADx-001 comprising a first phospholipid; a sterically bulky excipient that is capable of stabilizing the liposomal composition; a second phospholipid that is derivatized with a first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid that is derivatized with a second polymer, the second polymer being conjugated to a targeting ligand. The macrocyclic gadolinium-based imaging agent may be conjugated to a fourth phospholipid.Type: GrantFiled: January 29, 2021Date of Patent: September 14, 2021Assignee: Texas Children's HospitalInventors: Eric A. Tanifum, Ketankumar B. Ghaghada, Ananth V. Annapragada
-
Publication number: 20210252170Abstract: A liposomal composition (“ADx-003”) is provided, ADx-003 comprising a first phospholipid; a sterically bulky excipient that is capable of stabilizing the liposomal composition; a second phospholipid that is derivatized with a first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid that is derivatized with a second polymer, the second polymer being conjugated to a targeting ligand, the targeting ligand being represented by Formula I: wherein X is —CH2—, —CH2—CH2—, —CHO—, or —O—CO—; Y is —CH—CH?CH— or A and B are independently selected from C and N; R1, R2, R3, and R4 are independently selected from —H, halogen, —OH, and —CH3; and R5, R6, and R7 are independently selected from —H, halogen, —OH, —OCH3, —NO2, —N(CH3)2, C1-C6 alkyl, or a substituted or unsubstituted C4-C6 aryl group, except that when A and/or B is N the adjacent R5 and/or R7 is —H, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: February 12, 2021Publication date: August 19, 2021Applicants: Texas Children's Hospital, Alzeca Biosciences, LLCInventors: Eric A. Tanifum, Xianwei Sun, Ananth V. Annapragada, Carlo Medici
-
Publication number: 20210236662Abstract: A liposomal composition (“ADx-001”) is provided, ADx-001 comprising a first phospholipid; a sterically bulky excipient that is capable of stabilizing the liposomal composition; a second phospholipid that is derivatized with a first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid that is derivatized with a second polymer, the second polymer being conjugated to a targeting ligand. The macrocyclic gadolinium-based imaging agent may be conjugated to a fourth phospholipid.Type: ApplicationFiled: January 29, 2021Publication date: August 5, 2021Applicant: Texas Children's HospitalInventors: Eric A. Tanifum, Ketankumar B. Ghaghada, Ananth V. Annapragada
-
Publication number: 20210170055Abstract: A liposomal composition (“ADx-001”) is provided, ADx-001 comprising a first phospholipid; a sterically bulky excipient that is capable of stabilizing the liposomal composition; a second phospholipid that is derivatized with a first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid that is derivatized with a second polymer, the second polymer being conjugated to a targeting ligand. The macrocyclic gadolinium-based imaging agent may be conjugated to a fourth phospholipid.Type: ApplicationFiled: January 29, 2021Publication date: June 10, 2021Applicant: Texas Children's HospitalInventors: Eric A. Tanifum, Ketankumar B. Ghaghada, Ananth V. Annapragada
-
Publication number: 20200261605Abstract: Phospholipid-polymer-aromatic conjugates comprising binding ligands, liposome compositions including the phospholipid-polymer-aromatic conjugates, and binding ligands having an affinity for misfolded proteins are described. The phospholipid-polymer-aromatic conjugate may be represented by Structural Formula I: PL-AL-HP-X-BL (I). In Formula I, PL is a phospholipid, AL is an aliphatic linkage, HP is hydrophilic polymer, X is a link between the phospholipid-polymer and the binding ligand, and BL is polycyclic aromatic compound that functions as a binding ligand. The liposomal compositions may be useful for the imaging of misfolded and/or aggregated proteins.Type: ApplicationFiled: January 24, 2020Publication date: August 20, 2020Inventors: Ananth V. ANNAPRAGADA, Peter NILSSON, Carlo MEDICI, Eric A. TANIFUM
-
Publication number: 20200179540Abstract: Provided are aromatic compounds, phospholipid-polymer-aromatic conjugates comprising the aromatic compounds, and liposome compositions including the phospholipid-polymer-aromatic conjugates. The liposomal compositions may be useful for imaging of Alzheimer's Disease, for example, imaging of the amyloid-? plaque deposits characteristic of Alzheimer's Disease.Type: ApplicationFiled: February 14, 2020Publication date: June 11, 2020Inventors: Ananth V. Annapragada, Eric A. Tanifum, Mayank Srivastava
-
Patent number: 10124078Abstract: Lipid-based nanoparticle compositions are provided. The compositions generally comprise lipid-hydrophilic polymer-amyloid binding ligand conjugates, and may be liposomal compositions. The compositions, including the liposomal compositions, may be useful for imaging and/or the treatment of amyloid-? plaque deposits characteristic of Alzheimer's Disease.Type: GrantFiled: October 30, 2017Date of Patent: November 13, 2018Inventors: Ananth V. Annapragada, Jason L. Eriksen, Eric A. Tanifum, Indrani Dasgupta, Stephen C. Cook
-
Publication number: 20180043039Abstract: Lipid-based nanoparticle compositions are provided. The compositions generally comprise lipid-hydrophilic polymer-amyloid binding ligand conjugates, and may be liposomal compositions. The compositions, including the liposomal compositions, may be useful for imaging and/or the treatment of amyloid-? plaque deposits characteristic of Alzheimer's Disease.Type: ApplicationFiled: October 30, 2017Publication date: February 15, 2018Inventors: Ananth V. Annapragada, Jason L. Eriksen, Eric A. Tanifum, Indrani Dasgupta, Stephen C. Cook
-
Patent number: 9744251Abstract: Provided are aromatic compounds, phospholipid-polymer-aromatic conjugates comprising the aromatic compounds, and liposome compositions including the phospholipid-polymer-aromatic conjugates. The liposomal compositions may be useful for imaging of Alzheimer's Disease, for example, imaging of the amyloid-? plaque deposits characteristic of Alzheimer's Disease.Type: GrantFiled: October 8, 2015Date of Patent: August 29, 2017Inventors: Ananth V. Annapragada, Eric A. Tanifum, Mayank Srivastava
-
Publication number: 20160101197Abstract: Provided are aromatic compounds, phospholipid-polymer-aromatic conjugates comprising the aromatic compounds, and liposome compositions including the phospholipid-polymer-aromatic conjugates. The liposomal compositions may be useful for imaging of Alzheimer's Disease, for example, imaging of the amyloid-? plaque deposits characteristic of Alzheimer's Disease.Type: ApplicationFiled: October 8, 2015Publication date: April 14, 2016Inventors: Ananth V. Annapragada, Eric A. Tanifum, Mayank Srivastava
-
Patent number: 4952547Abstract: A catalyst for use in a process for oxidatively coupling methane to C.sub.2 and other hydrocarbons, including aromatic hydrocarbons, which is an iron-phosphorus-oxide catalyst having an iron to phosphorus ratio of from 0.1:1.0 to 2.0:1.0 is used.Type: GrantFiled: July 25, 1988Date of Patent: August 28, 1990Assignee: The Regents of the University of MichiganInventors: Ananth V. Annapragada, Erdogan Gulari